We recently published a list of Why These 10 Stocks Soared Today. In this article, we are going to take a look at where ...

We recently published a list of 10 Best Cancer Stocks to Invest in for Long-Term Gains. In this article, we are going to take ...

Q1 2025 Management View CEO Helen Torley emphasized the company’s focus on both organic and inorganic growth, with a strategy ...

Halozyme Therapeutics HALO has outperformed the market over the past 15 years by 4.64% on an annualized basis producing an ...

Return on Assets (ROA): Halozyme Therapeutics's financial strength is reflected in its exceptional ROA, which exceeds ...

Halozyme Therapeutics, Inc. ( NASDAQ: HALO) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Tram Bui - Vice President, Investor Relations & Corporate Communications Helen Torley - President & ...

Learn more about whether BioCryst Pharmaceuticals, Inc. or Halozyme Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Although the revenue and EPS for Halozyme Therapeutics (HALO) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare ...

SAN DIEGO (AP) — SAN DIEGO (AP) — Halozyme Therapeutics Inc. (HALO) on Tuesday reported first-quarter profit of $118.1 million. On a per-share basis, the San Diego-based company said it had profit of ...

First Quarter and Recent Corporate Highlights: On May 6, Halozyme announced a second $250 million share repurchase under the $750 million approved program from February 2024. In April 2025 ...

In recent trading, shares of Halozyme Therapeutics Inc (Symbol: HALO) have crossed above the average analyst 12-month target price of $68.12, changing hands for $70.14/share. When a stock reaches ...